Equities

Balchem Corp

Balchem Corp

Actions
Basic MaterialsChemicals
  • Price (USD)152.25
  • Today's Change-1.58 / -1.03%
  • Shares traded57.73k
  • 1 Year change+12.39%
  • Beta0.6780
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. The Company's segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. Through Specialty Products, it re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

  • Revenue in USD (TTM)929.56m
  • Net income in USD114.82m
  • Incorporated1967
  • Employees1.30k
  • Location
    Balchem Corp5 Paragon DriveMONTVALE 07645United StatesUSA
  • Phone+1 (845) 326-5600
  • Fax+1 (845) 326-5742
  • Websitehttps://balchem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Minerals Technologies Inc2.16bn93.80m2.76bn4.03k29.681.6614.701.282.882.8866.3651.510.63584.705.28535,957.302.743.813.234.4124.2023.744.316.521.754.910.37135.752.093.72-31.18-12.574.264.56
Tronox Holdings PLC2.92bn-348.00m3.18bn6.50k--1.69--1.09-2.22-2.2218.5811.920.4711.797.39448,615.40-5.624.68-6.525.4715.4022.66-11.939.051.091.260.593522.16-17.499.40-163.58--17.4122.67
Quaker Chemical Corp1.92bn117.87m3.22bn4.40k27.262.3217.081.686.576.57107.2477.330.69014.534.17437,028.203.801.904.372.1937.1234.335.513.061.983.800.355749.600.500517.62808.3310.8224.663.95
Innospec Inc1.94bn147.30m3.27bn2.40k22.262.7617.401.685.885.8877.4747.471.164.005.87808,083.308.786.6311.318.4430.8929.897.606.251.67--0.0028.89-0.75885.704.597.4120.739.64
Scotts Miracle-Gro Co3.43bn-347.70m3.71bn2.50k------1.08-6.22-6.2260.42-4.420.76952.693.591,371,600.00-7.802.79-10.733.6423.3529.25-10.142.661.050.89861.10190.70-9.505.9213.12--6.354.29
H.B. Fuller Company3.51bn154.01m4.24bn7.20k28.332.4013.441.212.752.7562.5832.470.7624.856.43487,801.503.253.343.783.9229.8727.114.274.371.232.800.508724.95-6.352.92-19.64-7.4311.785.53
Arcadium Lithium PLC890.20m230.90m4.63bn2.91k4.130.749216.845.211.041.042.035.750.14871.578.63306,015.803.93--4.47--54.6339.9626.4222.911.37--0.0773--8.5214.8020.6921.1134.76--
Balchem Corp929.56m114.82m5.04bn1.30k44.004.6729.695.423.533.5328.6033.270.57785.276.85713,946.307.147.377.718.1133.3931.4412.3511.821.727.100.219722.11-2.117.463.016.9413.9510.94
NewMarket Corporation2.69bn397.61m5.21bn2.00k13.074.5310.811.9441.5841.58281.58120.100.97763.595.841,346,183.0014.4912.8316.7715.9129.3726.5014.8211.511.6011.810.526230.44-2.403.3439.0711.17-8.344.80
Cabot Corp3.91bn443.00m5.44bn4.27k12.443.988.581.397.917.9169.8224.741.105.105.18916,119.9013.755.9018.748.5323.3221.1812.515.381.4712.000.4451.63-9.033.93112.1457.561.283.61
Element Solutions Inc2.33bn129.10m5.79bn5.30k44.722.4919.492.480.53470.54349.659.600.47444.365.07440,339.602.622.542.832.7840.0940.165.536.032.697.110.452135.01-8.483.54-37.43--13.16--
Olin Corp6.62bn353.30m6.07bn7.33k18.292.806.970.91682.782.7852.7118.190.84275.887.20904,176.904.404.945.415.9015.0418.155.225.660.79653.580.556228.56-27.12-0.3278-65.327.01-9.330.00
FMC Corp4.06bn1.22bn7.22bn6.60k5.931.675.131.789.758.9532.4534.540.34251.411.35615,227.3010.307.9115.8211.4239.1442.5630.0817.011.022.440.500230.30-22.670.923270.3521.58-8.1734.45
Data as of Jun 07 2024. Currency figures normalised to Balchem Corp's reporting currency: US Dollar USD

Institutional shareholders

57.42%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20244.60m14.27%
The Vanguard Group, Inc.as of 31 Mar 20243.84m11.91%
APG Asset Management NVas of 31 Mar 20243.04m9.41%
Wasatch Advisors LPas of 31 Mar 20241.88m5.83%
SSgA Funds Management, Inc.as of 31 Mar 20241.23m3.81%
Conestoga Capital Advisors LLCas of 31 Mar 20241.13m3.49%
Geode Capital Management LLCas of 31 Mar 2024846.21k2.62%
Geneva Capital Management LLCas of 31 Mar 2024763.47k2.37%
Dimensional Fund Advisors LPas of 31 Mar 2024691.48k2.14%
ClearBridge Investments LLCas of 31 Mar 2024506.14k1.57%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.